<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065802</url>
  </required_header>
  <id_info>
    <org_study_id>REB19-1281</org_study_id>
    <nct_id>NCT04065802</nct_id>
  </id_info>
  <brief_title>Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia Management</brief_title>
  <acronym>STAR VTM</acronym>
  <official_title>Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Libin Cardiovascular Institute of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Arrhythmia Radioablation (STAR) ablation is a safe and feasible option for&#xD;
      cardiomyopathy patients for management of refractory ventricular tachycardia.&#xD;
&#xD;
      STAR can be performed with available cardiac imaging, prior mapping/electrogram information,&#xD;
      and standard ECGs without a multi-electrode ECG vest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Hypotheses:&#xD;
&#xD;
        1. Stereotactic Arrhythmia Radioablation (STAR) ablation is a safe and feasible option for&#xD;
           cardiomyopathy patients for management of refractory ventricular tachycardia.&#xD;
&#xD;
        2. STAR can be performed with available cardiac imaging, prior mapping/electrogram&#xD;
           information, and standard ECGs without a multi-electrode ECG vest.&#xD;
&#xD;
      Study Objectives:&#xD;
&#xD;
        1. Evaluate the safety of STAR in a local cohort&#xD;
&#xD;
        2. Estimate effectiveness of STAR in reducing VT burden&#xD;
&#xD;
      Study Design: Prospective single center, single arm, non-randomized trial.&#xD;
&#xD;
      Number of patients: 20 patients&#xD;
&#xD;
      Study Duration: Enrollment will occur over three years and at least minimum follow up of six&#xD;
      months&#xD;
&#xD;
      Study Population: Adult patients with a cardiomyopathy and ventricular tachycardia who have&#xD;
      failed conventional anti-arrhythmic management.&#xD;
&#xD;
      Primary safety endpoint: Any treatment-related serious adverse events in the first 90 days.&#xD;
&#xD;
      Primary efficacy endpoint: Reduction in VT episodes tracked by ICD with a six week blanking&#xD;
      period.&#xD;
&#xD;
      Statistical methodology: Wilcoxon matched-pairs signed-ranks test to compare the number of&#xD;
      treated episodes before and after.&#xD;
&#xD;
      Assessment of events: Adjudicated by study investigators&#xD;
&#xD;
      Economic Analysis: Costs and resources required for STAR .Compare costs between the patients&#xD;
      undergoing STAR with conventional catheter-based VT ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Adult patients with a cardiomyopathy and ventricular tachycardia who have failed conventional anti-arrhythmic management.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of radiation treatment for VT reduction</measure>
    <time_frame>6 month period before treatment to the 6 month period after ablation with a 6 week blanking period post-treatment.</time_frame>
    <description>Reduction in VT burden tracked by ICD and defined as the difference between the number of ICD-treated VT/VF episodes comparing the 6 months prior to treatment to the 6 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety composite endpoint of radiation treatment-related pericarditis, pneumonitis, changes in cardiac structures, function, and/or ICD function.</measure>
    <time_frame>90 days after treatment</time_frame>
    <description>Any treatment-related serious adverse events including pericarditis, radiation pneumonitis, deterioration in cardiac function, new or worsening cardiac valve dysfunction, and implantable cardioverter defibrillator malfunction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>Six months</time_frame>
    <description>Six month survival after treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stereotactic Radioablation for Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Radioablation Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive radioablation to scar regions of the heart responsible for ventricular tachycardia</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radioablation</intervention_name>
    <description>External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias</description>
    <arm_group_label>Radioablation Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        18 years of age and have an implanted cardioverter defibrillator (ICD) with:&#xD;
&#xD;
          1. Structural heart disease: ischemic or non-ischemic cardiomyopathy diagnosed with&#xD;
             cardiac imaging demonstrating either segmental myocardial dysfunction, or presence of&#xD;
             scar.&#xD;
&#xD;
          2. At least one of the following monomorphic VT events despite prior attempted catheter&#xD;
             ablation (or contraindication for ablation), and despite treatment with a class III&#xD;
             antiarrhythmic drug (contraindicated, ineffective or not tolerated):&#xD;
&#xD;
        A: Sustained monomorphic VT documented on 12-lead ECG or rhythm strip terminated by&#xD;
        pharmacologic means, DC cardioversion or manual ICD Therapy.&#xD;
&#xD;
        B: ≥3 episodes of monomorphic VT treated with antitachycardia pacing (ATP), at least one of&#xD;
        which was symptomatic C: ≥ 5 episodes of monomorphic VT treated with antitachycardia pacing&#xD;
        (ATP) regardless of symptoms D: ≥1 appropriate ICD shocks, E: ≥3 monomorphic VT episodes&#xD;
        within 24 hours VT events must be confirmed by ECG/monitor or ICD download.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received prior radiotherapy to the anticipated treatment field&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable to unwilling to provide informed consent&#xD;
&#xD;
          -  New York Heart Association class IV heart failure or inotrope use limiting the safe&#xD;
             transport to the radiotherapy suite&#xD;
&#xD;
          -  Patients in whom the only ventricular arrhythmias are ventricular fibrillation,&#xD;
             torsade de pointes, or polymorphic ventricular tachycardia.&#xD;
&#xD;
          -  Active coronary ischemia in the last 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Kuriachan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikas Kuriachan, MD</last_name>
    <phone>4039443282</phone>
    <email>vpkuriac@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Wilton, MD</last_name>
    <phone>4032107102</phone>
    <email>sbwilton@ucalgary.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Mckeage</last_name>
      <phone>4032106047</phone>
      <email>jmckeage@ucalgary.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, Faddis M, Gleva M, Noheria A, Smith TW, Hallahan D, Rudy Y, Robinson CG. Noninvasive Cardiac Radiation for Ablation of Ventricular Tachycardia. N Engl J Med. 2017 Dec 14;377(24):2325-2336. doi: 10.1056/NEJMoa1613773.</citation>
    <PMID>29236642</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuculich PS, Robinson CG. Noninvasive Ablation of Ventricular Tachycardia. N Engl J Med. 2018 Apr 26;378(17):1651-1652. doi: 10.1056/NEJMc1802625.</citation>
    <PMID>29694814</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Vikas Kuriachan</investigator_full_name>
    <investigator_title>Clinical Associate Professor (Cardiology/EP)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The data will be anonymous. Given the small number of patients in the study individual treatments and outcomes maybe looked at.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

